American Thrombosis and Hemostasis Network

Recent papers from American Thrombosis and Hemostasis Network

1. Lack of Inhibitor Development in Previously Treated People With Haemophilia Switching Factor Products—Final Results of Athn 2: Factor Switching StudyHaemophilia · 2026
2. Research agenda and related workforce requirements inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research CollaborativeExpert Review of Hematology · 2026
3. Infrastructure and workforce development processes inspired by Lived Experience Experts and grounded in health equity for the Bleeding Disorders Research CollaborativeExpert Review of Hematology · 2026
4. VHA-guided resuscitation and post-24-hour survival in traumatic hemorrhage: a propensity- matched retrospective cohort study from ChinaFrontiers in Medicine · 2026
5. Human seminal plasma suppresses neutrophil antimicrobial functions and promotes bacterial survivalFrontiers in Immunology · 2026
6. Availability of direct oral anticoagulants testing among Italian anticoagulation clinics: a rapid evolution of clinical practiceBleeding Thrombosis and Vascular Biology · 2026
7. Heat intolerance: the challenge of returning to duty post-exertional heatstrokeFrontiers in Sports and Active Living · 2026
8. Diagnostic utility of the platelet-to-thrombin–antithrombin complex ratio in heatstroke: a single-center retrospective analysisInternational Journal of Hyperthermia · 2026
9. Bleeding Phenotypes in Inherited Platelet Function Disorders: Insights From the ATHNdatasetJournal of Pediatric Hematology/Oncology · 2026
10. Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 studyBlood Vessels Thrombosis & Hemostasis · 2026
11. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous ThromboembolismNew England Journal of Medicine · 2026
12. Contribution of Host Genetics and Maternal Inflammatory Bowel Disease to Fecal Calprotectin and Microbiota Composition During Early LifeJCC Plus · 2026
13. Uncovering distinct clinical phenotypes in disseminated intravascular coagulation through machine learning-enabled cluster analysisSHILAP Revista de lepidopterología · 2026
14. Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD TrialCirculation Cardiovascular Interventions · 2026
15. Assessing the impact of distance from primary hemophilia treatment center on annualized bleeding rates in people with inheritable bleeding disordersBlood · 2025
16. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History StudyHaemophilia · 2025
17. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History StudyHaemophilia · 2025
18. Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PADJournal of the American Heart Association · 2025
19. Inhibitors and Obesity: The Prevalence and Strength of Association in People With HaemophiliaHaemophilia · 2025
20. Indefinite anticoagulation with reduced-intensity direct oral anticoagulants in patients with splanchnic vein thrombosis. An international practice surveyBlood Coagulation & Fibrinolysis · 2025